- Home
- / Protagonist Therapeutics
Protagonist Therapeutics
Stock Price
$48.4
2024-10-29
Market Capitalization
$2.9 B
2024-10-29
Revenue
$46 M
FY, 2025
Protagonist Therapeutics Summary
Company Summary
- Overview
- Protagonist Therapeutics is a biopharmaceutical company engaged in discovering and developing peptide-based therapeutic drugs. It develops a peptide technology platform used to create treatments for blood disorders and inflammatory and immunomodulatory diseases.
- Type
- Public
- Status
- Active
- Founded
- 2006
- HQ
- Newark, CA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Suneel Gupta, Chief Development Officer
Arturo Molina, Chief Medical Officer
Matthew Gosling, Executive Vice President, General Counsel
LocationsView all
2 locations detected
Newark, CA HQ
United States
7707 Gateway Blvd suite 140
Saint Lucia, QLD
Australia
306 Carmody Rd
Protagonist Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $56.4M
- Net income (Q1, 2026)
- $3.8M
- Cash (Q1, 2026)
- $193.7M
- EBIT (Q1, 2026)
- ($3.6M)
- Enterprise value
- $2.7B